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The burden of chronic disease in Europe
The burden of chronic disease in Europe is characterized
by several positive trends, but also some major new chal-
lenges. On one hand there has been an important and
consistent reduction in mortality, particularly in young and
middle age that has led to a substantial increase in life
expectancy in all 28 countries within the EU (EU28) in the
last 40 years. Even within the relatively recent period of
2003–2013, there was an increase in life expectancy of
3.2 years for men and 2.5 years for women overall in the
EU (Fig. 1) [1]. While these trends represent a major
success in public health, they hide less positive develop-
ments, including major health disparities. Across Europe
major differences in life expectancy exist, of over 10 years
for men and over 7 years for women (Table 1) [1]. These
differences are most extreme between southern Mediter-
ranean Europe and the countries of central Europe and the
Baltic region.
Not all of this increase in life expectancy is ‘healthy life
expectancy’. For example, on average in Europe, a man
and a woman at age 65 will have a life expectancy of
approximately 18 years and 21 years respectively. How-
ever, only 9 of these will be years lived in good health [2].
The remaining are characterized by age-related morbidity
due to one or more chronic diseases (multimorbidity),
resulting in an important reduction in quality of life and
increasing cost to health care budgets.
Demographic changes in the age structure of the European
population are also going to have an important effect on
absolute numbers of disease events even assuming no major
changes in age-specific incidence rates. For example, the
absolute number of cancer cases in the 28 EU countries is
projected to increase due to demographic effects from 2.75
million in 2015 to over 3.1 million cases per year by 2025 [3].
The number of people who are living with cancer has also
been increasing. It is estimated that there are currently 16–17
million European citizens who either are being treated for
cancer or are in post-treatment long term remission, and this
number will also increase substantially over the next
10–20 years. Regarding specific causes of death, 85% of
deaths in the EU are due to chronic diseases including cancer,
cardiovascular disease, chronic respiratory disease, diabetes,
and mental illness. Cancer from all causes is the predominant
cause of death before the age of 65, whereas cardiovascular
disease is the predominant cause of death after age 65.
The financial burden associated with chronic
disease in Europe
The financial costs associated with treating chronic dis-
eases are extremely high, and given that the average age of
European populations is increasing, chronic diseases will
continue to place an important pressure on national bud-
gets. The economic burden of cancer care on its own was
estimated at 126 billion euros in 2009, approximately 40%
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of which was health care costs, 40% was due to produc-
tivity losses and lost working days, and 20% due to costs
related to informal care [4]. Healthcare costs in the Euro-
pean Union currently make up between 7% and 11% of
overall GDP expenditure (Table 2) [2]. Chronic diseases
also have important societal costs as they depress wages,
workforce participation and labour productivity, as well as
increase early retirement, high job turnover and disability.
Treatment costs for some chronic diseases are also rapidly
increasing, especially for treatment of late stage cancers.
The demand for expensive health care interventions is
likely to increase substantially over the medium term in
Europe at a time of limited economic growth and stagnant
national health budgets. These trends represent genuine and
important concerns for all national governments in Europe,
and place increasing pressure on the ability to deliver
sustainable health services. The co-occurrence of multiple
chronic diseases in an individual, typically referred to as
multimorbidity, is also becoming increasingly common, as
it is more prevalent at older ages. Over 50 million people
in Europe have more than one chronic disease, due to either
random co-occurrence, possible shared underlying risk
profile, or synergies in disease development [5]. The costs
of treating and caring for patients with multiple conditions
tend to increase dramatically with the number and com-
bination of comorbidities, although the pattern varies for
certain specific diseases [2, 6]. A greater understanding of
the underlying causes of multimorbidity is essential in
order to curb the increasing prevalence of this condition.
An aging European population will undoubtedly result in
an increase in the burden of chronic diseases in Europe,
placing an enormous burden on national health budgets. The
Global Action Plan for the prevention and control of non-
communicable disease (NCDs) identified an overall goal for
a 25% relative reduction in premature deaths (before the age
70) by 2025 [7]. This highlights the urgent need to identify
cost-effective and evidence-based public health policies and
interventions that are suitable for the European population,
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Fig. 1 Life expectancy at birth,
EU-28, 2002–2014. Eurostat
Statistics Explained [2]
Table 1 Life expectancy at birth in European Union in 2014
Country Total Males Females
Spain 83.3 80.4 86.2
Italy 83.2 80.7 85.6
Cyprus 82.8 80.9 84.7
France 82.8 79.5 86.0
Luxembourg 82.3 79.4 85.2
Sweden 82.3 80.4 84.2
Malta 82.1 79.8 84.2
Netherlands 81.8 80.0 83.5
Austria 81.7 79.2 84.0
Greece 81.5 78.9 84.1
Belgium 81.4 78.8 83.9
Ireland 81.4 79.3 83.5
United Kingdom 81.4 79.5 83.2
Finland 81.3 78.4 84.1
Portugal 81.3 78.0 84.4
Germany 81.2 78.7 83.6




Denmark 80.7 78.7 82.8
Czech Republic 78.9 75.8 82.0
Croatia 77.9 74.7 81.0
Poland 77.8 73.7 81.7
Estonia 77.4 72.4 81.9
Slovakia 77.0 73.3 80.5
Hungary 76.0 72.3 79.4
Romania 75.0 71.4 78.7
Lithuania 74.7 69.2 80.1
Bulgaria 74.5 71.1 78.0
Latvia 74.5 69.1 79.4
Bold indicates the numbers for the European Union as a whole and
thus shows countries with life expectancy higher or lower than EU
Eurostat Statistics Explained [1]
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The role of population cohorts and evidence based
prevention
Europe has been a leader in developing large population
cohorts that include collection of extensive biological
samples. The two most prominent examples include UK
Biobank that recruited 500,000 people aged 40–69 years
between 2006 and 2010 from across the UK (http://www.
ukbiobank.ac.uk), and the EPIC cohort that undertook
recruitment of 521,000 participants from 1993–1999 in 10
European countries, with study participants mostly invited
from the general population in an age range of 35–70 years
(http://epic.iarc.fr/). As of 2007, in the framework of the
European ESFRI programme of the EC, a large fraction of
the European cohorts (mostly population biobanks), clini-
cal biobanks and twin registries have established the
European biobanking infrastructure BBMRI (Biobanking
and Biomolecular Research Infrastructure), which has
obtained a formal ERIC (European Research Infrastructure
Consortium) status in 2013. Participants of the UK Bio-
bank study and several other recent population biobanks,
underwent detailed health and lifestyle interviews and
provided blood, urine, saliva and more recently occasion-
ally even stool samples for future analyses. Follow-up for
disease outcomes including cancer, cardiovascular and
respiratory diseases is by a number of mechanisms. A
novel feature of UK Biobank and other contemporary
biobanks is that their primary purpose is to be used as a
scientific resource by ‘external’ investigators in the scien-
tific community anywhere in the world [8]. The future
promise of such resources for health research can be
illustrated with the achievements of the EPIC cohort: in the
last 25 years, over 80,000 newly incident cancer cases,
18,000 cases of ischemic heart disease (IHD), 6000 cere-
brovascular accidents and 14,000 cases of Type 2 diabetes
have been reported, producing over 600 scientific publi-
cations 400 of which making use of the stored biological
samples.
The more recent cohorts mostly have sample sizes
between 10,000 and 100,000 individuals (Fig. 2), while in
the last 10 years a new phase of cohort development
emerged, with even[ 100,000 participants. The total size
of population cohorts in Europe stands at over 2.5 million
participants, although with a strong disparity in cohort
coverage, mainly due to economic restraints. Western and
Northern Europe are strongly covered, including up to 5%
of the entire population in some countries like Finland and
the Netherlands, while in Eastern Europe large population
cohorts are rare.
Much of our understanding of the driving forces of ill-
health and premature mortality derive from analyses of
these large cohorts. The second half of the 20th century
was characterised by a substantial improvement in public
health and life expectancy in practically all parts of the
world [9]. When Jerry Morris wrote ‘Uses of epidemiol-
ogy’ in 1955 [10], one-third of men aged 35 in the UK
could be expected to die before the age of 65, whereas that
figure is now less than 15%. The reasons for this are partly
clinical, including better treatment and access to care, and
partly societal, including better housing, vast reductions in
road traffic accidents and improved nutrition, although a
substantial part is due to the demonstration of the important
negative effects of tobacco smoking on lung cancer and
subsequently over 19 other cancers, as well as numerous
other maladies including common vascular and respiratory
diseases [11]. The weight of the evidence has been from
population based cohort studies that minimise certain bia-
ses and allow for accurate estimation of absolute risk
effects. The 2004 IARC monograph evaluation of tobacco
smoke and involuntary smoking [12] included results from
over 40 different cohorts including 13 from Europe, 19
from North America and 12 from Asia. Similarly, we now
have accurate estimates of the role of other important risk
factors on public health outcomes, including for elevated
body mass and hypertension [13]. Although a potential
beneficial effect of alcohol at low doses is still debated, the
role of excess alcohol consumption in premature mortality
has also been evaluated through large cohort studies, with a
particular focus on populations in Russia and east Europe
where large numbers of adults drink to excess [14]. Cohorts
Table 2 Health care
expenditures in fractions of
gross domestic product (GDP)
More than 10/% 8–10% 7–8% Less than 7%
Country GDP (%) Country GDP (%) Country GDP (%) Country GDP (%)
Netherlands 11.8 Portugal 9.7 Hungary 7.7 Luxembourg 6.8
France 11.2 Spain 9.2 Bulgaria 7.7 Lithuania 6.4
Germany 10.9 Greece 9.2 Slovakia 7.6 Poland 6.3
Belgium 10.9 Sweden 9.1 Czech Republic 7.4 Latvia 6.0
Denmark 10.6 Finland 8.7 Cyprus 7.3 Estonia 5.8
Austria 10.4 Slovenia 8.6 Croatia 7.0 Romania 5.5
Eurostat Statistics Explained [2]
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that focus on specific subgroups such as workers have been
fundamental in identifying occupational exposures that
lead to cancer and other outcomes, and have resulted in
much improved workplaces [15]. Cohorts that focus on
children have also been instrumental for identifying key
stages of childhood that are instrumental for healthy
development, as well as more specific outcomes such as the
role of sleeping position in sudden infant death syndrome
(SIDS) [16, 17]. Large population cohorts are therefore the
basic tool of epidemiology and population health, and even
though many of our health indicators have improved over
recent decades they remain as essential as ever in
evaluating the various ways in which our rapidly changing
society can impact on health.
Using cohorts to assess the population impact
of known risk factors and identify novel risk
factors
A recent example of how European cohorts can contribute
with evidence relevant for policy making is an analysis
from 265,000 individuals from the EPIC cohort with
complete risk factor data, 11,930 of whom died during the
Fig. 2 Prospective European cohorts with at least 10,000 participants
and including baseline collection of biological samples. *Cohort
acronyms by country: Estonia: EGCUT = Estonian Genome Centre,
University of Tartu; Germany: KORA = KOoperative gesundheits-
forschung in der Region Augsburg, NAKO = German national
cohort; Italy: CUORE = Cohort of Italian Adult Women and Men,
M-s study = Moli-sani Study, CHRIS = Cooperative Health
Research in South Tyrol Study; Netherlands: NLCS = Netherlands
Cohort Study; Norway: MoBa = Norwegian Mother and Child
Cohort Study, HUNT = Nord-Trøndelag Health Study; Sweden:
NSHDS = Northern Sweden Health and Disease Study, COSM/
SMC = Cohort of Swedish men/Swedish Mammography Cohort;
Turkey: BHS = Balcova Heart Study; United Kingdom:
BGS = Breakthrough Generations, UKHLS = The UK Household
Longitudinal Study. **EPIC (The European Prospective Investigation
into Cancer and Nutrition) includes the following centres: EPIC-
Denmark (56 K), EPIC-France (20 K), EPIC-Germany (Potsdam &
Heidelberg) (50 K), EPIC-Greece (28 K), EPIC-Italy (47 K), EPIC-
Netherlands (36 K), EPIC-Norway (9 K), EPIC-Spain (39 K), EPIC-
Sweden (53 K), and EPIC-United Kingdom (43 K)
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follow-up before the age of 70. Six common risk factors
could collectively explain 57% of premature deaths
(Table 3) [18]. These data illustrated the predominant
impact of tobacco smoking which explained 31% of pre-
mature deaths. Further, smokers with otherwise healthy
lifestyle characteristics had similar death rates as did never
smokers who presented multiple ‘‘unhealthy’’ risk factors,
including a poor diet, obesity, hypertension, physical
inactivity and consumption of more than two alcoholic
drinks per day [18]. Overall, over 95% of non-smokers
with additional healthy characteristics reached the age of
70, whereas only 80% of female smokers with additional
unhealthy characteristics and 64% of men reached the age
of 70. Another study, in Estonia and Finland, has high-
lighted that a large portion of short-term all-cause mortality
risk can be caught in the combined levels of just 4 NMR-
metabolic biomarkers [19]. These studies clearly demon-
strate how cohort data can be used to evaluate the relative
importance of common risk factors or readily measurable
metabolites for the risk of premature death. This informa-
tion would be highly relevant to public health measures to
curb premature death in Europe.
Large population cohorts that cover heterogeneous
populations with a diverse range of exposures and chronic
disease incidence are also the most appropriate setting for
further elucidating the unknown causes of chronic disease.
Even while diseases such as cancer have been extensively
studied, many causes are still unknown, with only about
50% of cancer incidence accounted for by known causes
[20]. While it is likely that a proportion of cancers, and
perhaps even other chronic diseases, do have a true
stochastic pathology, it is also clear from international
disease trends and differences that important unknown
causes remain [21]. A co-ordinated analysis of suspected
causes across numerous population cohorts does however
require that an important component of standardization is
undertaken prior to any analysis being feasible.
Behaviour modification and large scale studies
Exposures and lifestyle patterns are generally not static but
change over time. A clear example is that of smoking, with
many individuals who take up the habit, usually in the late-
teens, quitting smoking in middle or late age. Past infor-
mation on smoking habits is relatively easy to obtain from
questionnaires when individuals are recruited into cohorts,
resulting in accurate and risk estimates of past smoking
habits and quitting at various ages [22]. This is not however
the norm, and a limitation of many cohorts is that they are
restricted by the information that is gained at study
recruitment, with often minimal amounts of information
regarding historical changes in many other types of expo-
sure. Multiple interviews over time can help to identify
changes in future exposure status, although they are not the
norm for cohort studies, primarily because of cost and the
difficulty in getting study participants to agree to multiple
re-interviews. Cohort studies are therefore not ideal for
measuring the effect of changing exposure over time.
Given the observational nature of cohort studies, other
important limitations include confounding, confounding by
indication and reverse causation. The impact of represen-
tativeness has also been discussed at length recently, and is
of particular relevance given that some very large cohorts
such as UK Biobank have participation rates of less than
10% of those invited to participate [23–25]. The potential
for collider bias, whereby exposures and additional risk
factors are associated with the probability of inclusion, may
be underappreciated. An additional concern is that many
findings related to protective effects of diet and nutritional
components have not been replicated in subsequent ran-
domized studies, indicating that the initial findings were
due to confounding. Reverse causation is generally thought
to be a limited problem for prospective studies, although
recent genetic evidence from genes that correlate with
alcohol consumption would seem to suggest that the much
vaunted protective effect of moderate levels of alcohol on
cardiovascular disease may be better explained by indi-
viduals prone to developing the disease avoiding alcohol
altogether [26]. One alternative to overcome this challenge
is through building large scale randomized studies into
prospective cohorts. Although randomized studies that
subsequently repurpose themselves as cohorts are relatively
common, the opposite of conducting randomized trials
within established cohorts is much rarer. One positive
example is the Golestan cohort in Iran of 50,000 individ-
uals that has a trial of cardiovascular disease mortality
reduction using a polypill [27].
Table 3 Population attributable fractions (AF) of pre-mature mor-
tality in 10 European countries for common risk factors
Risk factor AF (%) 95% CI
Tobacco smoking 31 (31–32%)
Poor diet 14 (12–16%)
High waist-to-hip ratio 10 (8–12%)
High blood pressure 9 (7–11%)
Physical inactivity and low physical activity 7 (5–9%)
High alcohol use 4 (3–4%)
Combined 57 (55–59%)
Muller et al. [18]
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Cohort studies in the era of precision medicine
The potential for population cohorts to contribute to the
understanding of why some individuals develop specific
diseases, and how they respond to particular treatments is
the primary rationale behind the recent initiative in the US
to build a national cohort of one million US citizens [28].
Central to the research into human biological variation
which is underpinning the drive towards personalized
medicine, is the genotyping of hundreds of thousands of
genetic variants across the human genome in millions of
people, a hitherto unprecedented scale. This allows for
evaluation of the vast majority of genetic variation due to
common single nucleotide polymorphisms as in genome-
wide associations studies (GWAS). One important aspect
of the US ‘Precision Medicine’ initiative was to provide
genetic data on a large number of people with extensive
phenotype information and clinical follow-up. Develop-
ment of this large cohort of one million adults in the US is
currently underway.
Genetic research into common diseases in Europe is on
the verge of another period of rapid discovery due to the
genotyping of large numbers of cohort participants. The
most notable is the genotyping of all 500,000 participants
in UK Biobank using a genome-wide genotyping array. As
of July 2017, genome-wide data on all 500,000 individuals
has been made available to the scientific community, with
additional exome sequencing of at least 50,000 individuals
underway. The UK Biobank is performing additional
phenotyping for a large panel of circulating biomarkers.
The advent of large-scale genome-wide data has opened up
several avenues for innovative research aiming to under-
stand causes and mechanisms underlying complex dis-
eases. These include Mendelian randomization type studies
that provide additional evidence on the causal relevance of
lifestyle risk factors in the absence of the various biases
that are sometimes difficult to exclude in traditional
observational epidemiology [29].
Cohort studies have had their greatest success for
exposure that are relatively stable and easy to measure (e.g.
smoking and obesity), whereas ubiquitous environmental
exposures or those occurring during specific time periods
have been a lot more problematic to study. The developing
fields of lifecourse epidemiology and exposomics, whereby
the totality of environmental exposures from conception
onwards are evaluated, is a novel and exciting approach to
studying the role of the environment in disease develop-
ment [21, 30].
The importance of population cohorts
for identifying individuals at high risk of disease
Another key aim of the precision medicine paradigm in the
context of disease prevention is developing methods and
tools that allow identifying individuals who are likely to
develop specific diseases in the near future. For instance,
being able to identify particular subgroups or even indi-
viduals who are at high risk of imminent cardiovascular
events would allow intense interventions, with the potential
of saving many lives across Europe. Evaluation of the
feasibility, usefulness, safety and cost-effectiveness of CT
screening is currently ongoing in the Swedish CArdioPul-
monary BioImage Study [31]. Another aspect of individual
disease prevention is improving the identification of indi-
viduals that are most likely to benefit from cancer screen-
ing. There are currently a number of screening programs in
place in many European countries, in particular for breast
cancer (by mammography), cervical cancer (by cervical
pap-smear) and colorectal cancer (by faecal occult blood
test followed by recto-sigmoidoscopy or colonoscopy),
with lung cancer screening also being considered. Detect-
ing these cancers through screening at pre-neoplastic or
early stages when they remain curable can measurably
reduce their mortality. On the other hand, the screening
efficacy, including number of subjects needed to screen to
detect a cancer and the subsequent cost implications has
generally been less than optimal. There are also negative
effects of screening, including the markedly high risk of
false positives with subsequent clinical follow-up and
possible iatrogenic consequences. For instance it has
recently been demonstrated that it is possible to reduce
lung cancer mortality by 20% through early detection [32].
However, the NLST study also highlighted several
important negative aspects associated with CT screening in
terms of morbidity associated with overdiagnosis, treat-
ment of benign nodules and financial costs. Furthermore,
many lung cancer cases do not satisfy the NLST screening
criteria, and are therefore not eligible for screening. Within
two large European prospective cohort studies (UK Bio-
bank and EPIC) it has been estimated that only about 50%
of the incident lung cancer patients were eligible for
screening according to the NLST criteria [32]. Taken
together, these data clearly illustrate the urgent need to
improve the eligibility criteria for CT screening using
comprehensive risk prediction models, and multiple studies
suggest that incorporating biomarkers of lung cancer risk
could substantially improve such models. Prospective
cohorts will have a key role in providing prediction tools
for common chronic diseases given the need for pre-diag-
nostic data and biospecimens. Candidates for blood based
early detection markers including circulating tumour DNA
746 P. Brennan et al.
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[33], recently the focus of a large private initiative, micro
RNA and protein based biomarkers [21]. Incorporation of
technological expertise from biotech companies will likely
be fundamental to translating scientific developments in the
area into practical screening tools. While moving ahead
with development of prediction tools for identifying high
risk individuals, it will also be important to ensure that the
limitations of this approach are not forgotten. As discussed
over 30 years ago by Geoffrey Rose, there will remain a
need to also undertake a broad population approach to
prevention, where one attempts to modify the risk distri-
bution among all [34].
The importance of collaboration
Prospective cohort studies are instrumental in evaluating
the impact of a wide range of risk factors for specific
diseases, as well as for developing disease-prediction tools.
However, because they recruit study participants prior to
disease onset and follow them throughout the life-course,
prospective studies need to be of very large size with
adequate follow-up time to be able to study common dis-
eases in a reliable manner. Moreover, studying all but the
most common diseases is challenging in single prospective
cohorts. Evaluating the consistency in study results across
different populations will also be crucial in assessing the
importance of promising findings, in particular when con-
sidering translating them into public health measures. To
maximize achieving this, it is crucial to make European
cohorts compliant with the FAIR and FAIR-Health prin-
ciples, where FAIR stands for ‘Findable, Accessible,
Interoperable and Reusable’ [35], and the ‘health’ exten-
sion refers to additional requirements for health data of
human subjects: traceable quality and reproducibility
records and compliance with national and international
privacy protection principles. These latter have been
developed within BBMRI-ERIC (Holub et al., manuscript
submitted) anticipating on consistency with the upcoming
European Open Science Cloud.
Cohort infrastructure: needs and gaps
The UK Biobank study as well as several large interna-
tional initiatives like ENGAGE [36], GIANT [37] and
CHARGE [38] have led the way on developing or inte-
grating large population cohorts with extensive lifestyle,
genomic and metabolomics characterization, and making
materials and data available to the broad scientific com-
munity. While the large national biobank are exemplary in
their efforts, on their own they will not be sufficient for the
broad European public health and research community. As
demonstrated above, the UK is but one aspect of the
European public health experience, and even a cohort of
500,000 will have limitations with respect to study size.
Initiatives like EPIC have significant strengths in this
regard, covering many countries in Europe and with
sometimes very long follow-up and often extensive geno-
mic and more recently metabolomic characterization.
Other large new national cohorts are under recruitment, and
will complement the established initiatives (Fig. 2). In
order to initiate discussion regarding how population
cohorts across Europe can work together, leaders of these
cohorts have joined together to initiate an informal
‘European cohort consortium’ (ECC). This partnership
includes 40 cohorts ranging in size from 10,000 up to
520,000 individuals and with a total potential sample size
of over 2.5 million individuals.
If Europe is to retain a leadership position in population
based health research, as well as continue to provide evi-
dence for improving public health, then several key actions
need to be undertaken. First of all, mechanisms need to be
established that allow studies to be conducted across these
cohorts. These include efforts to ensure access to outside
investigators, as well as initiatives to harmonize lifestyle
and exposure data, as well as outcome measures for mor-
bidity and mortality. These cohorts need to be viewed as an
essential European research resource, contributing to the
research facilities under construction in the BBMRI-ERIC
infrastructure, including coordinated ELSI (Ethical, Legal
and Social Implications) and IT platforms, a common
sample and metadata catalogue and standardized quality
assessment and control. The true value of these cohorts will
only come through extensive genetic and phenotypic
characterization. Assays for broad panels of genetic, phe-
notypic and infectious markers are becoming cheaper,
especially when done on a large series. Further, one needs
to recognize that large parts of Europe do not have large
established population cohorts, in particular in central and
Eastern Europe, and efforts need to be made to fill this gap.
Finally, we appreciate that such a bold initiative will
only go ahead if there is political will to support it. The
management and development of large cohorts require
considerable resources, with both EPIC and UK Biobank
costing in the region of 100 million euros to establish.
While modest national investments have been possible in
the establishment of national BBMRI nodes and the
national contributions to BBMRI-ERIC, none of this
reflects the actual foundation cost of each nation’s bio-
banks proper, let alone the essential investments needed for
maintenance and innovations. The US national cohort has
been allocated $130 million for the current budget year
alone. Europe is in the envious position where many of the
cohorts are already in place, and what is required is a
structure to bring them together. Given the scientific
Chronic disease research in Europe and the need for integrated population cohorts 747
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potential of such a large European cohort initiative, as well
as the importance of informing public health policy across
the continent, a more relevant question may be whether we
can afford not to build it.
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